Get notified when MBRX files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts
NASDAQ: MBRX Moleculin Biotech, Inc. 8-K

Moleculin announces market assessment results for Annamycin in relapsed AML

Filed June 5, 2026 · Period ending June 5, 2026 · ~1 min read

Key Changes

  • medium

    Company released results from an independent market landscape assessment evaluating Annamycin, its drug candidate for relapsed/refractory acute myeloid leukemia (R/R AML). Such assessments typically analyze commercial opportunity, competitive positioning, and market potential.

    8-K: Press Release verify on EDGAR →

This preview is just the start — the full report includes the narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (ISNR 10-Q) is open in full — no account needed.

Partner

Trade MBRX commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Was this report useful?
View original filing on SEC.gov Press release (Ex 99.1) on EDGAR ↗

Source-verified from EDGAR · Narrative written by AI · Jun 5, 2026 · How we verify